Applied Therapeutics, Inc. (APLT) - רווח נקי למניה (EPS TTM)

Reliable cold chains and diversified suppliers ensure the seamless operation of Applied Therapeutics (APLT) laboratories. Management focuses on the quality of clinical data to successfully bring drugs to market. Business prospects depend on the approval of aldose reductase inhibitors. The current level of annual net income per share illustrates the fundamental earnings, and -0.10 captures the magnitude of this parameter.

An analysis of the 12-month earnings per share history highlights the specific nature of Applied Therapeutics (APLT) as a developer of orphan drugs. This metric reflects the actual cash return of the business per security, excluding one-time accounting distortions. It measures capitalization efficiency by dividing total net income by the total number of shares. For the biopharmaceutical sector, this indicator serves as a marker of financial stability while awaiting FDA approval. The stability of this figure confirms the company's ability to maintain its balance sheet without excessive borrowing.